Saxenda (liraglutide) has been recording dominant sales in the growing obesity treatment market in Korea.

Therefore, the drug is expected to monopolize the obesity treatment market until other new obesity treatments such as ‘Wegovy (semaglutide, Novo Nordisk)’ and ‘Mounjaro (tirzepatide, Lilly)’ are released in Korea.

#According to the market investigation institution IQVIA on the 25th, Novo Nordisk’s Saxenda showed a surge in quarterly prescription sales recently.

More specifically, Saxenda’s sales recorded KRW 10.4 billion in Q1 last year, then increased to KRW 15.4 billion in Q2, then recorded a quarterly best record of KRW 16.6 in Q3 last year. In other words, th